Serving the Society Since 1986
Advanced Search
Volume 31 Issue 6
December 2016
    Citation: Junjie Zhang, Mao Tian, Zanxian Xia, Pinghui Feng. Roles of IκB kinase ε in the innate immune defense and beyond .VIROLOGICA SINICA, 2016, 31(6) : 457-465.  http://dx.doi.org/10.1007/s12250-016-3898-y
    shu

    Roles of IκB kinase ε in the innate immune defense and beyond

    • 1.

      Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles 90033, USA

    • 2.

      State Key Laboratory of Medical Genetics and School of Life Sciences, Central South University, Changsha 410008, China

    • Corresponding author: Junjie Zhang, junjie.zhang@usc.edu, ORCID: 0000-0003-3812-3850
    • Received Date: 27 October 2016
      Accepted Date: 22 December 2016
      Published Date: 28 December 2016
      Available online: 01 December 2016
    • IκB kinase ε (IKKε) is a non-canonical IκB kinase that is extensively studied in the context of innate immune response. Recently, significant progress has been made in understanding the role of IKKεin interferon (IFN) signaling. In addition to its roles in innate immunity, recent studies also demonstrate that IKKε is a key regulator of the adaptive immune response. Specifically, IKKε functions as a negative feedback kinase to curtail CD8 T cell response, implying that it can be a potential therapeutic target to boost antiviral and antitumor T cell immunity. In this review, we highlight the roles of IKKε in regulating IFN signaling and T cell immunity, and discuss a few imminent questions that remain to be answered.
    • 加载中

      1. Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR. 2006. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature, 441: 595-600.
          doi: 10.1038/nature04678

      2. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol, 77: 7945-7956.
          doi: 10.1128/JVI.77.14.7945-7956.2003

      3. Bharaj P, Wang YE, Dawes BE, Yun TE, Park A, Yen B, Basler CF, Freiberg AN, Lee B, Rajsbaum R. 2016. The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to Inhibit the IKKepsilon Kinase-Mediated Type-Ⅰ IFN Antiviral Response. PLoS Pathog, 12: e1005880.
          doi: 10.1371/journal.ppat.1005880

      4. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. 2007. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell, 129: 1065-1079.
          doi: 10.1016/j.cell.2007.03.052

      5. Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M, Itie A, Wakeham A, Shahinian A, Henzel WJ, Elia AJ, Shillinglaw W, Mak TW, Cao Z, Yeh WC. 2000. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J, 19: 4976-4985.
          doi: 10.1093/emboj/19.18.4976

      6. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. 2015. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol, 33: 257-290.
          doi: 10.1146/annurev-immunol-032414-112240

      7. Cardenas WB, Loo YM, Gale M, Jr., Hartman AL, Kimberlin CR, Martinez-Sobrido L, Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol, 80: 5168-5178.
          doi: 10.1128/JVI.02199-05

      8. Challa S, Guo JP, Ding X, Xu CX, Li Y, Kim D, Smith MA, Cress DW, Coppola D, Haura EB, Cheng JQ. 2016. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Res, 76: 4418-4429.
          doi: 10.1158/0008-5472.CAN-16-0069

      9. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR. 2009. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell, 138: 961-975.
          doi: 10.1016/j.cell.2009.06.046

      10. Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P. 2010. Novel cross-talk within the IKK family controls innate immunity. Biochem J, 434: 93-104.

      11. Clark K, Plater L, Peggie M, Cohen P. 2009. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem, 284: 14136-14146.
          doi: 10.1074/jbc.M109.000414

      12. Clement JF, Meloche S, Servant MJ. 2008. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res, 18: 889-899.
          doi: 10.1038/cr.2008.273

      13. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol, 4: 491-496.

      14. Gulen MF, Bulek K, Xiao H, Yu M, Gao J, Sun L, Beurel E, Kaidanovich-Beilin O, Fox PL, DiCorleto PE, Wang JA, Qin J, Wald DN, Woodgett JR, Jope RS, Carman J, Dongre A, Li X. 2012. Inactivation of the enzyme GSK3alpha by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity, 37: 800-812.
          doi: 10.1016/j.immuni.2012.08.019

      15. Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. 2009. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol, 175: 324-333.
          doi: 10.2353/ajpath.2009.080767

      16. Hasan M, Yan N. 2016. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res, 111: 336-342.
          doi: 10.1016/j.phrs.2016.04.008

      17. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, Kawai T, Hoshino K, Takeda K, Akira S. 2004. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med, 199: 1641-1650.
          doi: 10.1084/jem.20040520

      18. Hutti JE, Porter MA, Cheely AW, Cantley LC, Wang X, Kireev D, Baldwin AS, Janzen WP. 2012. Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKepsilon. PLoS One, 7: e41494.
          doi: 10.1371/journal.pone.0041494

      19. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC. 2009. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell, 34: 461-472.
          doi: 10.1016/j.molcel.2009.04.031

      20. Johnson EN, Lee YM, Sander TL, Rabkin E, Schoen FJ, Kaushal S, Bischoff J. 2003. NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J Biol Chem, 278: 1686-1692.
          doi: 10.1074/jbc.M210250200

      21. Kaukinen P, Sillanpaa M, Nousiainen L, Melen K, Julkunen I. 2012. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J Med Virol, 85: 71-82.

      22. Kiani A, Garcia-Cozar FJ, Habermann I, Laforsch S, Aebischer T, Ehninger G, Rao A. 2001. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood, 98: 1480-1488.
          doi: 10.1182/blood.V98.5.1480

      23. Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. 2013. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A, 110: 12414-12419.
          doi: 10.1073/pnas.1220674110

      24. Liang D, Gao Y, Lin X, He Z, Zhao Q, Deng Q, Lan K. 2011. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKepsilon. Cell Res, 21: 793-806.
          doi: 10.1038/cr.2011.5

      25. Liang Q, Fu B, Wu F, Li X, Yuan Y, Zhu F. 2012. ORF45 of Kaposi's sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKepsilon and TBK1 as an alternative substrate. J Virol, 86: 10162-10172.
          doi: 10.1128/JVI.05224-11

      26. Lin D, Zhang M, Zhang MX, Ren Y, Jin J, Zhao Q, Pan Z, Wu M, Shu HB, Dong C, Zhong B. 2015. Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6. Proc Natl Acad Sci U S A, 112: 11324-11329.
          doi: 10.1073/pnas.1509968112

      27. Lu LL, Puri M, Horvath CM, Sen GC. 2008. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem, 283: 14269-14276.
          doi: 10.1074/jbc.M710089200

      28. McLaughlin-Drubin ME, Munger K. 2008. Viruses associated with human cancer. Biochim Biophys Acta, 1782: 127-150.
          doi: 10.1016/j.bbadis.2007.12.005

      29. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T. 2004. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci U S A, 101: 233-238.
          doi: 10.1073/pnas.2237236100

      30. Moore PS, Chang Y. 2010. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer, 10: 878-889.

      31. Muller MR, Rao A. 2010. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol, 10: 645-656.
          doi: 10.1038/nri2818

      32. Peant B, Gilbert S, Le Page C, Poisson A, L'Ecuyer E, Boudhraa Z, Bienz MN, Delvoye N, Saad F, Mes-Masson AM. 2016. IkappaB-Kinase-epsilon (IKKepsilon) over-expression promotes the growth of prostate cancer through the C/EBP-beta dependent activation of IL-6 gene expression. Oncotarget. doi: 10. 18632/oncotarget. 11629.

      33. Perwitasari O, Cho H, Diamond MS, Gale M, Jr. 2011. Inhibitor of kappaB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J Biol Chem, 286: 44412-44423.
          doi: 10.1074/jbc.M111.285205

      34. Peters RT, Liao SM, Maniatis T. 2000. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell, 5: 513-522.
          doi: 10.1016/S1097-2765(00)80445-1

      35. Platanias LC. 2005. Mechanisms of type-Ⅰ-and type-Ⅱ-interferon-mediated signalling. Nat Rev Immunol, 5: 375-386.
          doi: 10.1038/nri1604

      36. Postow MA, Callahan MK, Wolchok JD. 2015. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol, 33: 1974-1982.
          doi: 10.1200/JCO.2014.59.4358

      37. Prins KC, Cardenas WB, Basler CF. 2009. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol, 83: 3069-3077.
          doi: 10.1128/JVI.01875-08

      38. Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, Martinez-Romero C, Patel JR, Morrison J, Pisanelli G, Miorin L, Laurent-Rolle M, Moulton HM, Stein DA, Fernandez-Sesma A, tenOever BR, Garcia-Sastre A. 2014. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKepsilon kinase-mediated antiviral response. Immunity, 40: 880-895.
          doi: 10.1016/j.immuni.2014.04.018

      39. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, Olefsky JM, Saltiel AR. 2013. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med, 19: 313-321.
          doi: 10.1038/nm.3082

      40. Ren Y, Zhao Y, Lin D, Xu X, Zhu Q, Yao J, Shu HB, Zhong B. 2016. The Type Ⅰ Interferon-IRF7 Axis Mediates Transcriptional Expression of Usp25 Gene. J Biol Chem, 291: 13206-13215.
          doi: 10.1074/jbc.M116.718080

      41. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science, 300: 1148-1151.
          doi: 10.1126/science.1081315

      42. Shen RR, Hahn WC. 2010. Emerging roles for the non-canonical IKKs in cancer. Oncogene, 30: 631-641.

      43. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, Kanamaru A, Akira S. 1999. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol, 11: 1357-1362.
          doi: 10.1093/intimm/11.8.1357

      44. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of type Ⅰ interferon signaling. Science, 340: 207-211.
          doi: 10.1126/science.1235214

      45. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. 2007. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science, 315: 1274-1278.
          doi: 10.1126/science.1136567

      46. Verhelst K, Verstrepen L, Carpentier I, Beyaert R. 2013. IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochem Pharmacol, 85: 873-880.
          doi: 10.1016/j.bcp.2013.01.007

      47. Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, Johannes J, Larsen NA, Su Q, Tucker JA, Whitston D, Wu J, Zhang HJ, Zinda M, Chuaqui C. 2012. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett, 22: 2063-2069.
          doi: 10.1016/j.bmcl.2012.01.018

      48. Wang Y, Lu X, Zhu L, Shen Y, Chengedza S, Feng H, Wang L, Jung JU, Gutkind JS, Feng P. 2013. IKK epsilon kinase is crucial for viral G protein-coupled receptor tumorigenesis. Proc Natl Acad Sci U S A, 110: 11139-11144.
          doi: 10.1073/pnas.1219829110

      49. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. 2013. Blockade of chronic type Ⅰ interferon signaling to control persistent LCMV infection. Science, 340: 202-207.
          doi: 10.1126/science.1235208

      50. Wu X, Qi X, Qu B, Zhang Z, Liang M, Li C, Cardona CJ, Li D, Xing Z. 2013. Evasion of antiviral immunity through sequestering of TBK1/IKKepsilon/IRF3 into viral inclusion bodies. J Virol, 88: 3067-3076.

      51. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, Wang CY, Guan KL. 2011. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A, 108: 6474-6479.
          doi: 10.1073/pnas.1016132108

      52. Yu J, Zhou X, Chang M, Nakaya M, Chang JH, Xiao Y, Lindsey JW, Dorta-Estremera S, Cao W, Zal A, Zal T, Sun SC. 2015. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat Commun, 6: 6074.
          doi: 10.1038/ncomms7074

      53. Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, Xu M, Chen ZJ. 2010. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell, 141: 315-330.
          doi: 10.1016/j.cell.2010.03.029

      54. Zhang J, Feng H, Zhao J, Feldman ER, Chen SY, Yuan W, Huang C, Akbari O, Tibbetts SA, Feng P. 2016. IkappaB Kinase epsilon is an NFATc1 kinase that inhibits T cell immune response. Cell Rep, 16: 405-418.
          doi: 10.1016/j.celrep.2016.05.083

      55. Zhao W. 2013. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett, 587: 542-548.
          doi: 10.1016/j.febslet.2013.01.052

      56. Zitvogel L, Kroemer G. 2012. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology, 1: 1223-1225.
          doi: 10.4161/onci.21335

    • 加载中

    Figures(2)

    PDF

    Article Metrics

    Article views(6143) PDF downloads(17) Cited by()

    Related
    Proportional views

      Roles of IκB kinase ε in the innate immune defense and beyond

        Corresponding author: Junjie Zhang, junjie.zhang@usc.edu
      • 1. Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles 90033, USA
      • 2. State Key Laboratory of Medical Genetics and School of Life Sciences, Central South University, Changsha 410008, China
      • Received Date: 27 October 2016
      • Accepted Date: 22 December 2016
      • Published Date: 28 December 2016

      Abstract: IκB kinase ε (IKKε) is a non-canonical IκB kinase that is extensively studied in the context of innate immune response. Recently, significant progress has been made in understanding the role of IKKεin interferon (IFN) signaling. In addition to its roles in innate immunity, recent studies also demonstrate that IKKε is a key regulator of the adaptive immune response. Specifically, IKKε functions as a negative feedback kinase to curtail CD8 T cell response, implying that it can be a potential therapeutic target to boost antiviral and antitumor T cell immunity. In this review, we highlight the roles of IKKε in regulating IFN signaling and T cell immunity, and discuss a few imminent questions that remain to be answered.

        HTML

      INTRODUCTION